The present invention provides a compound of a formula (I):
wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
Substituted bipiperidine intermediates and derivatives thereof
申请人:AstraZeneca AB
公开号:EP1493743A1
公开(公告)日:2005-01-05
A compound of formula (Xllla):
wherein: L2 is hydrogen, tert-butoxycarbonyl or benzyl; t is 0 or 1; m and p are, independently, 0, 1 or 2; X is CH2, C(O), O, S, S(O), S(O)2 or NR37; provided that when m and p are both 1 then X is not CH2; and R1 has specified values.
一种式(Xllla)化合物:
其中L2 是氢、叔丁氧基羰基或苄基;t 是 0 或 1;m 和 p 分别是 0、1 或 2;X 是 CH2、C(O)、O、S、S(O)、S(O)2 或 NR37;但当 m 和 p 均为 1 时,X 不是 CH2;R1 具有指定值。
INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
申请人:AstraZeneca AB
公开号:EP1604982A1
公开(公告)日:2005-12-14
The invention provides a compound of formula (X) or (XVIII):
wherein: R1 is optionally substituted aryl or optionally substituted heterocyclyl; and R2 is hydrogen or C1-6 alkyl; said compounds can be used for preparing modulators of chemokine (especially CCR3) activity.